Potential Interactions of Active Compounds of Morinda citrifolia (Noni) on Targets Involved in Human Diseases
Scientia Pharmaceutica · 20.07.2026 · 94 (3) · 62
DOI: 10.3390/scipharm94030062 ↗Kurz gefasst
Fachartikel in der Zeitschrift Scientia Pharmaceutica, online erschienen am 20.07.2026. Verfasst von Diana Rodríguez-Vera und 7 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 158 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Secretaria de Investigación y Posgrado del Instituto Politécnico Nacional, Secretaria de Ciencias, Humanidades, Tecnología e Innnovación.
Abstract (Originalsprache)
Morinda citrifolia (Noni) is well known as a plant with therapeutic potential and is also attractive to the food and cosmetic industries. Traditional medicine supports its use, mainly for the treatment of metabolic disorders and chronic inflammation but also for certain types of cancer. Noni has been the subject of considerable interest within the scientific community due to its purported health benefits. However, despite its growing popularity and extensive traditional use, significant gaps remain in the empirical understanding of its properties, mechanisms, and potential applications. To understand its biological activity, particular attention has been given to several chemical compounds present in its leaves and fruits, as they have been identified as bioactive agents. Moreover, several studies support the idea that specific flavonoids and anthraquinones from noni act on enzymes and transporters associated with glucose and lipid metabolism in humans. Its involvement in cardiovascular, neurological, metabolic, and inflammatory regulation across several high-burden diseases expands the potential medical applications of noni. This narrative review presents the current state of knowledge, highlighting preclinical studies that suggest the mechanisms of action underlying the observed effects, including theoretical approaches proposing specific interactions between noni compounds and proteins associated with human diseases as potential therapeutic targets. It also identifies areas where information remains insufficient and proposes future research directions for pharmacological applications, including the need for additional clinical studies and more comprehensive pharmacokinetic and toxicological evaluations.
Förderung
- Secretaria de Investigación y Posgrado del Instituto Politécnico Nacional
- Secretaria de Ciencias, Humanidades, Tecnología e Innnovación
Zitieren
APA
Rodríguez-Vera, D., Farfán-García, E. D., Estevez-Fregoso, E., Reséndiz-Albor, A. A., Arciniega-Martínez, I. M., Madrigal-Santillán, E., Morales-González, J. A., & Soriano-Ursúa, M. A. (2026). Potential Interactions of Active Compounds of Morinda citrifolia (Noni) on Targets Involved in Human Diseases. Scientia Pharmaceutica, 94(3), 62. https://doi.org/10.3390/scipharm94030062
Vancouver
Rodríguez-Vera D, Farfán-García ED, Estevez-Fregoso E, Reséndiz-Albor AA, Arciniega-Martínez IM, Madrigal-Santillán E, et al. Potential Interactions of Active Compounds of Morinda citrifolia (Noni) on Targets Involved in Human Diseases. Scientia Pharmaceutica. 2026;94(3):62. doi:10.3390/scipharm94030062
BibTeX
@article{RodrguezVera2026,
author = {Rodríguez-Vera, Diana and Farfán-García, Eunice D. and Estevez-Fregoso, Elizabeth and Reséndiz-Albor, Aldo A. and Arciniega-Martínez, Ivonne Maciel and Madrigal-Santillán, Eduardo and Morales-González, Jose A. and Soriano-Ursúa, Marvin A.},
title = {Potential Interactions of Active Compounds of Morinda citrifolia (Noni) on Targets Involved in Human Diseases},
journal = {Scientia Pharmaceutica},
year = {2026},
volume = {94},
number = {3},
pages = {62},
doi = {10.3390/scipharm94030062}
}
EUVIMED